Best Stocks Under $2 Right Now → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Aptose BiosciencesNASDAQ:APTOStock Price: $1.50 (-$0.02)P/E Ratio: -0.19Market Cap: $23.57 millionAverage Trading Volume: 93,946 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $36.50 (2,333.3% Upside)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Clearside BiomedicalNASDAQ:CLSDStock Price: $1.56 (-$0.15)P/E Ratio: -2.94Market Cap: $116.56 millionAverage Trading Volume: 347,576 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.75 (204.5% Upside)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.#3 - TeraWulfNASDAQ:WULFStock Price: $1.73 (-$0.05)Market Cap: $416.77 millionAverage Trading Volume: 20.22 million sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.65 (111.0% Upside)TeraWulf Inc., together with its subsidiaries, operates as a digital asset technology company in the United States. It develops, owns, and operates bitcoin mining facility sites in New York and Pennsylvania. TeraWulf Inc. was founded in 2021 and is based in Easton, Maryland.#4 - Checkpoint TherapeuticsNASDAQ:CKPTStock Price: $1.89 (-$0.03)Market Cap: $44.47 millionAverage Trading Volume: 618,392 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $22.60 (1,095.8% Upside)Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.#5 - Vor BiopharmaNYSE:VORStock Price: $1.92 (-$0.01)P/E Ratio: -1.01Market Cap: $130.19 millionAverage Trading Volume: 275,329 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $15.19 (691.0% Upside)Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.#6 - Integra ResourcesNYSEAMERICAN:ITRGStock Price: $0.74 (-$0.02)P/E Ratio: -1.15Market Cap: $50.77 millionAverage Trading Volume: 102,776 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.75 (408.8% Upside)Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.Urgent new message from Porter Stansberry (Ad)I’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r#7 - Ur-EnergyNYSEAMERICAN:URGStock Price: $1.48 (+$0.01)P/E Ratio: -12.33Market Cap: $416.81 millionAverage Trading Volume: 3.41 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.76 (86.7% Upside)Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. Its flagship property is the Lost Creek project comprising a total of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 35,400 acres located in the Great Divide Basin, Wyoming. The company was incorporated in 2004 and is headquartered in Littleton, Colorado.#8 - Unicycive TherapeuticsNASDAQ:UNCYStock Price: $1.43 (-$0.03)P/E Ratio: -0.82Market Cap: $49.69 millionAverage Trading Volume: 353,716 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.30 (480.4% Upside)Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.#9 - CleneNASDAQ:CLNNStock Price: $0.41 (+$0.01)P/E Ratio: -0.78Market Cap: $52.25 millionAverage Trading Volume: 871,681 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.80 (1,817.4% Upside)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.#10 - RallybioNASDAQ:RLYBStock Price: $1.63 (+$0.01)P/E Ratio: -0.89Market Cap: $61.63 millionAverage Trading Volume: 244,659 sharesConsensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.60 (673.0% Upside)Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.#11 - Milestone PharmaceuticalsNASDAQ:MISTStock Price: $1.49 (+$0.04)P/E Ratio: -1.08Market Cap: $49.89 millionAverage Trading Volume: 366,759 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.20 (651.7% Upside)Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.The only AI company you should be looking at (Ad)This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>>#12 - Gamida CellNASDAQ:GMDAStock Price: $0.37 (+$0.05)P/E Ratio: -1.23Market Cap: $39.07 millionAverage Trading Volume: 2.95 million sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.40 (1,359.5% Upside)Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.#13 - Seres TherapeuticsNASDAQ:MCRBStock Price: $0.76 (-$0.03)P/E Ratio: -0.84Market Cap: $114.51 millionAverage Trading Volume: 4.94 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.75 (1,053.9% Upside)Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.#14 - DZSNASDAQ:DZSIStock Price: $1.31 (-$0.11)P/E Ratio: -0.74Market Cap: $40.82 millionAverage Trading Volume: 192,300 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.67 (408.9% Upside)DZS Inc. provides access and optical networking infrastructure and cloud software solutions in the Americas, Europe, the Middle East, Africa, and Asia. The company offers access edge solutions through DZS Velocity, including voice, high-definition and ultra-high-definition video, highspeed internet access, and business class services; switching and routing products; and XCelerate for increasing the velocity with which service providers can leap to multi-gigabit services. It also provides subscriber edge solutions through DZS Helix comprising optical network terminals (ONTs) and smart gateway solutions for fiber to the x (FTTx) deployment; and connected premises products, consisting of indoor/outdoor ONTs and gateways. In addition, the company offers optical edge solutions through DZS Chronos and DZS Saber, which provides solutions for mobile operators and service providers that enables them to upgrade their mobile fronthaul/midhaul/backhaul systems and migrate to fifth generation wireless technologies. Further, it provides cloud software solutions through DZS Cloud that offers a commercial, carrier-grade network-slicing enabled orchestration platform, which supports open RAN and 4G/5G networks. The company was formerly known as DASAN Zhone Solutions, Inc. and changed its name to DZS Inc. in August 2020. DZS Inc. was founded in 1996 and is headquartered in Plano, Texas.#15 - Eos Energy EnterprisesNASDAQ:EOSEStock Price: $0.96 (-$0.03)P/E Ratio: -0.45Market Cap: $195.52 millionAverage Trading Volume: 5.50 million sharesConsensus Rating: Moderate Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.08 (530.5% Upside)Eos Energy Enterprises, Inc. designs, manufactures, and markets zinc-based energy storage solutions for utility, commercial and industrial, and microgrid markets in the United States. The company's flagship product is the Eos Znyth DC system, a battery that can be used as an alternative to Li-ion batteries. Eos Energy Enterprises, Inc. was founded in 2008 and is headquartered in Edison, New Jersey.#16 - Cara TherapeuticsNASDAQ:CARAStock Price: $0.91 (+$0.03)P/E Ratio: -0.42Market Cap: $49.60 millionAverage Trading Volume: 778,539 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.75 (974.5% Upside)Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Did you make $29,000 two days with AI options trades? (Ad)What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy#17 - X4 PharmaceuticalsNASDAQ:XFORStock Price: $0.92P/E Ratio: -1.17Market Cap: $154.46 millionAverage Trading Volume: 1.40 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.20 (246.6% Upside)X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.#18 - Gold RoyaltyNYSEAMERICAN:GROYStock Price: $1.93 (-$0.07)P/E Ratio: -27.57Market Cap: $281.24 millionAverage Trading Volume: 605,509 sharesDividend Yield: 1.02%<Consensus Rating: Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.28 (70.1% Upside)Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. It focuses on acquiring royalties, streams, and similar interests at varying stages of the mine life cycle to build a portfolio offering near, medium, and longer-term attractive returns for its investors. The company's portfolio consists of net smelter return royalties ranging from 0.5% to 2.0% on 17 gold properties. Gold Royalty Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.#19 - FiscalNoteNYSE:NOTEStock Price: $1.75P/E Ratio: -2.01Market Cap: $226.15 millionAverage Trading Volume: 988,755 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.44 (153.6% Upside)FiscalNote Holdings, Inc. operates as technology company. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. The company delivers that intelligence through its suite of public policy and issues management products, as well as powerful tools to manage workflows, advocacy campaigns, and constituent relationships. It serves a customer base that includes businesses comprising the Fortune 100 companies, government agencies, law firms, professional services organizations, trade groups, and non-profits. The company is headquartered in Washington, District of Columbia.#20 - Aeva TechnologiesNYSE:AEVAStock Price: $1.01 (+$0.02)P/E Ratio: -1.55Market Cap: $264.51 millionAverage Trading Volume: 1.71 million sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.29 (126.9% Upside)Aeva Technologies, Inc. designs 4D LiDAR-on-chips in the United States, Thailand, Europe, the Middle East, and Asia. The company develops its products using frequency modulated continuous wave sensing technology. It offers 4D LiDAR sensing system with embedded software for automotive, industrial, and security applications; and a silicon photonics engine and software algorithms for industrial automation and consumer device applications. The company was founded in 2017 and is based in Mountain View, California.#21 - Gossamer BioNASDAQ:GOSSStock Price: $1.38 (-$0.08)P/E Ratio: -0.99Market Cap: $311.30 millionAverage Trading Volume: 1.08 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.35 (287.7% Upside)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.#22 - Tigo EnergyNASDAQ:TYGOStock Price: $0.98 (-$0.03)Market Cap: $57.57 millionAverage Trading Volume: 98,177 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.05 (619.4% Upside)Tigo Energy, Inc. develops module-level power electronics (Flex MLPE) and module optimizer technology for the solar industry. It offers solar optimizers. The company also provides software solutions, which include module-level monitoring software that manages utility, commercial, and residential PV arrays; and a mobile application for solar array management. In addition, it offers communication solutions, such as gateways; Maximizer Management Unit that communicates between the optimizers and the inverter; Cloud Connect, an on-site interface for modules, inverters, and other accessories to serve firefighters and installers; and Energy Intelligence (EI) solution, a digital platform to optimize the installer experience around commissioning, monitoring, and maintaining fleets of solar installations. The company serves residential, commercial and utility, PPA and 3rd-Party finance, and schools and government markets. It sells its products through distributors. Tigo Energy, Inc. was formerly known as Tergotech, Inc. and changed its name to Tigo Energy, Inc. in August 2007. The company was incorporated in 2007 and is based in Campbell, California with an additional office in Tuscany, Italy. The company has operations in Japan, China, Israel, Australia, Brazil, and Taiwan.#23 - Energy VaultNYSE:NRGVStock Price: $1.64P/E Ratio: -2.41Market Cap: $235.42 millionAverage Trading Volume: 850,411 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $4.44 (170.6% Upside)Energy Vault Holdings, Inc. develops and sells energy storage solutions. The company offers battery energy storage systems for shorter-duration energy storage needs; gravity energy storage systems, including EVx solution; green hydrogen energy storage systems; hybrid energy storage systems; and energy management software platform that orchestrates the management of one or more diverse storage mediums. Its solutions allow utilities, independent power producers, and large energy users to manage their power portfolios and efficiently dispatch power. Energy Vault Holdings, Inc. is based in Westlake Village, California.#24 - Coppernico MetalsOTCMKTS:CPPMFStock Price: $0.04P/E Ratio: 0.39Market Cap: $7.50 millionAverage Trading Volume: 27,240 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.25 (12,042.9% Upside)Copper Mountain Mining Corporation engages in the mining, exploration, and development of mineral properties in Canada. It explores for copper, gold, and silver deposits. The company holds 75% interests in the Copper Mountain mine comprising 135 crown-granted mineral claims, 145 located mineral claims, 14 mining leases, 12 fee simple properties, and seven cell claims that covers an area of approximately 6,354 hectares located to the south of Princeton, British Columbia. Copper Mountain Mining Corporation was incorporated in 2006 and is headquartered in Vancouver, Canada. As of June 20, 2023, Copper Mountain Mining Corporation operates as a subsidiary of Hudbay Minerals Inc.#25 - Karyopharm TherapeuticsNASDAQ:KPTIStock Price: $1.47 (-$0.04)P/E Ratio: -1.18Market Cap: $169.15 millionAverage Trading Volume: 1.91 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.67 (285.5% Upside)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Insider Selling of Amazon Spikes in Q1, but it's Not Time to Sell Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off 2 Dollar Stores Taking Different Paths to Profitability S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback? MarketBeat Week in Review – 3/11 – 3/15 These 3 Stocks Just Entered Overbought Territory Adobe Stock Reaches Turning Point as Market Outlook Resets Analysts Lead These Markets: The Most Upgraded Stocks in Q1 Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.